Offer - Urjas Oil for just ₹ 1 X
Glipijub M Tablet is a prescription drug, available for use as Tablet. The alternative uses of Glipijub M Tablet have also been explained below.
The optimal dosage of Glipijub M Tablet is largely dependent on the individual's body weight, medical history, gender and age. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. Refer to the dosage section for a detailed discussion.
The most common side effects of Glipijub M Tablet are Stomach Upset, Difficulty urinating, Hypoglycemia (Low blood sugar level). Besides the aforementioned side effects, there are other adverse effects of Glipijub M Tablet as well, which are listed below. Usually, these side effects of Glipijub M Tablet go away soon, and do not persist beyond the duration of the treatment. Consult your doctor if these side effects become worse or stay for a longer duration.
In addition, Glipijub M Tablet's effect is Moderate during pregnancy and Severe for lactating mothers. It is important to know if Glipijub M Tablet has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Glipijub M Tablet related warnings section.
Individuals suffering from medical conditions like Congestive Heart Failure (CHF), Anemia, Shock must refrain from the use of Glipijub M Tablet since this can cause severe adverse effects. Some other conditions that can be affected by Glipijub M Tablet are listed in the contraindications section below.
Drug interactions for Glipijub M Tablet have been reported in the medical literature. A complete list of these interactions is given below.
You should also be aware that Glipijub M Tablet is safe while driving, and is addiction.
Glipijub M Tablet is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
13 - 18 years (Adolescent) |
|
Adult |
|
Geriatric |
|
Is the use of Glipijub M Tablet safe for pregnant women?
Glipijub M may have some side effects during pregnancy. Pregnant women should discontinue the use of Glipijub M, and talk to their doctor, if they notice any discomfort.
Is the use of Glipijub M Tablet safe during breastfeeding?
Taking Glipijub M may lead to serious side effects if you are breastfeeding. Glipijub M should not be taken by breastfeeding women unless prescribed by the doctor.
What is the effect of Glipijub M Tablet on the Kidneys?
Information about safety of Glipijub M for kidney is not available since scientific research on this topic is yet to be done.
What is the effect of Glipijub M Tablet on the Liver?
In the absence of any scientific study on the side effects of Glipijub M on the liver, information on safety of Glipijub M for liver is unavailable.
What is the effect of Glipijub M Tablet on the Heart?
Information about safety of Glipijub M for heart is not available since scientific research on this is yet to be done.
Glipijub M Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Glipijub M Tablet unless your doctor advises you to do so -
Is this Glipijub M Tablet habit forming or addictive?
Glipijub M Tablet does not cause addiction.
Interaction between Food and Glipijub M Tablet
Due to the absence of research, it is difficult to say how Glipijub M Tablet and food will interact.
Interaction between Alcohol and Glipijub M Tablet
Due to lack of research, nothing can be said about side effects of consuming alcohol while taking Glipijub M Tablet.
Yes, you can take Glipijub M with a beta-blocker. People with diabetes tend to develop heart disease or stroke at an earlier age than the general population. One reason for this is that high glucose levels increase your risk of high blood pressure (hypertension). No harmful interactions are seen between them. However, a recent study suggests that beta-blockers can decrease the plasma level of Glipijub M and long-term use can increase lactic acid and uric acid in the blood.
Glipijub M is used with a proper diet and exercise program, to treat diabetes. It is also used with other medication to reduce the high blood sugar. It is used in a patient with type2 diabetes. It is also used in the treatment of polycystic ovarian syndrome (PCOS) and cancer.
Yes, Glipijub M can cause night sweat, the exact mechanism of sweating is not known. But some research suggests that Glipijub M causes hypoglycemia (low blood sugar) especially at night which can cause night sweats. Need to monitor your blood glucose level regularly, and talk to your doctor as your dose of Glipijub M may need to be adjusted.
Glipijub M contain metformin, is an oral antidiabetic drug which belongs to the class of biguanide. It is the first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight. It is also used in the treatment of polycystic ovary syndrome. Moreover, it also reduces the risk of cardiovascular complications of diabetes.
Glipijub M increases the sensitivity of insulin, young women with PCOS often have elevated insulin levels and are more likely to develop diabetes. It is often prescribed for women with PCOS to help prevent diabetes. A lifestyle that includes healthy nutrition and daily exercise is the most important part of a PCOS treatment plan.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Glucophage® (metformin hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 275-276
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 825-826